Item 9 Labs Corp. (INLB)
Item 9 Labs Corp. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Phoenix, AZ, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $70,181. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -143.1%. Its beta of 0.14 implies it has historically moved less than the broad market.
Based in the United States, Item 9 Labs Corp. operates as a comprehensive cannabis company, encompassing both vertical integration in cannabis operations and the franchising of dispensaries. The firm produces a wide spectrum of cannabis and related goods, such as raw flower, various concentrates, distillates, and necessary hardware. These cannabis and derived technologies and products are then supplied to consumers in Arizona via licensed retail dispensaries. Complementing its production activities, the company also develops and offers medical and adult-use cannabis dispensary franchises under its distinct Unity Rd brand. The main office for Item 9 Labs Corp. is found in Phoenix, Arizona.
Item 9 Labs Corp. is most often compared with the following Healthcare names: